This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abraham, W. T. Search for Related Content PubMed Articles by Abraham, W. T. Social Bookmarking                   What's this?

Pharmacologic Management of Chronic Heart Failure: A Review

Section of Heart Failure and Cardiac Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH

Standard drug therapy of systolic heart failure has been evaluated in large-scale randomized clinical trials and includes angiotensin-converting enzyme (ACE) inhibi tors, which should be used as first-line therapy, diuret ics for the management of extracellular fluid volume excess, and digoxin. In combination with ACE inhibitors and diuretics, with or without digoxin, some β-adrener gic receptor blockers attenuate disease progression and improve outcome in mild-to-moderate systolic heart failure. The pharmacologic management of chronic dia stolic heart failure is largely empirical and directed at reducing symptoms. Symptoms caused by increased ventricular filling pressures may be diminished by diuret ics and nitrovasodilators. Some calcium channel antago nists and most β-blockers prolong diastolic filling time by slowing heart rate, thereby improving the symptoms of diastolic heart failure.

Seminars in Cardiothoracic and Vascular Anesthesia, Vol. 2, No. 3, 168-190 (1998)
DOI: 10.1177/108925329800200302


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?